Hydrocortone

Hydrocortone is an oral tablet formulation that contains the corticosteroid hydrocortisone as its active ingredient. Marketed in the European Union as a prescription (Rx) product, it belongs to the glucocorticoid therapeutic class and is used under medical supervision. The medication is supplied without a specified strength on the label, and it is intended for systemic administration for treatment and management.

Hydrocortone is prescribed for several endocrine, inflammatory, and immune‑mediated conditions where systemic glucocorticoid activity is required.

- Replacement therapy in primary or secondary adrenal insufficiency. - Management of acute exacerbations of chronic inflammatory diseases such as rheumatoid arthritis or systemic lupus erythematosus. - Short‑term control of severe allergic reactions, including angioedema and drug‑induced hypersensitivity. - Adjunctive treatment for certain autoimmune disorders, for example inflammatory bowel disease or multiple sclerosis relapses. - Supportive therapy in severe asthma or chronic obstructive pulmonary disease (COPD) exacerbations when oral steroids are indicated.

Oral hydrocortisone may cause a range of adverse reactions, which are generally categorized by frequency and clinical significance. These reactions can vary in intensity and may require medical evaluation.

Common: - Increased appetite or weight gain. - Mild gastrointestinal discomfort such as nausea or dyspepsia. - Fluid retention leading to peripheral edema. - Mood changes, including irritability or mild anxiety. - Skin thinning or easy bruising.

Serious: - Significant hyperglycemia or new‑onset diabetes mellitus. - Severe hypertension or cardiovascular complications. - Osteoporosis or increased risk of fractures with prolonged use. - Susceptibility to opportunistic infections due to immunosuppression. - Adrenal suppression leading to secondary adrenal insufficiency. - Psychiatric disturbances such as psychosis.

Before initiating Hydrocortone, clinicians should evaluate several patient‑specific factors to minimize risks and ensure appropriate use.

- Assess for active infections, as glucocorticoids can worsen bacterial, viral, or fungal diseases. - Screen for uncontrolled diabetes, hypertension, or cardiovascular disease, which may be exacerbated. - Evaluate bone health, especially in patients with osteoporosis or a history of fractures. - Consider the potential for adrenal suppression; tapering may be required after prolonged therapy. - Use caution in pregnant or breastfeeding individuals, given limited safety data. - Review concomitant medications that may increase the risk of electrolyte imbalance or gastrointestinal bleeding.

Hydrocortone can alter the pharmacokinetics or pharmacodynamics of other agents, making awareness of drug interactions essential.

Avoid: - Concurrent use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone exposure. - Combination with other systemic glucocorticoids, which can increase the risk of systemic side effects.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) due to heightened risk of gastrointestinal ulceration or bleeding. - Anticoagulants such as warfarin, as glucocorticoids may affect coagulation parameters. - Vaccines, particularly live attenuated vaccines, because immunosuppression can diminish vaccine efficacy. - Diuretics, which may potentiate fluid‑electrolyte disturbances.